FGF23 and hyperphosphatemia: Deregulations in bone and mineral metabolism, including hyperphosphatemia, 25-hydroxy vitamin D3 (25[OH]-vitamin D3) deficiency, hyperparathyroidism, and high levels of the phosphaturic hormone fibroblast growth factor 23 (FGF23), have been associated with adverse outcomes in various populations (9–14).